Relay Therapeutics (RLAY)
NASDAQ:RLAY
US Market
Holding RLAY?
Track your performance easily

Relay Therapeutics (RLAY) Ownership - Who Owns Relay Therapeutics?

324 Followers

Relay Therapeutics (RLAY) Ownership Overview

33.94%26.69%15.54%23.84%
33.94% Insiders
15.54% Other Institutional Investors
23.84% Public Companies and
Individual Investors
The ownership structure of Relay Therapeutics (RLAY) stock is a mix of institutional, retail and individual investors. Approximately 42.23% of the company’s stock is owned by Institutional Investors, 33.94% is owned by Insiders and 23.84% is owned by Public Companies and Individual Investors.
The ownership structure of Relay Therapeutics (RLAY) stock is a mix of institutional, retail and individual investors. Approximately 42.23% of the company’s stock is owned by Institutional Investors, 33.94% is owned by Insiders and 23.84% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Jul 01, 2024
Donald A Bergstrom
President, R&d
xxxxxxxxxxxxx
$4056
Jul 01, 2024
Peter Rahmer
Chief Corporate Development Officer
xxxxxxxxxxxxx
$1534
Jul 01, 2024
xxxxxxxxxxxxx
$1847
Jul 01, 2024
xxxxxxxxxxxxx
$1847

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Mar 31, 2024
xxxxxxxxxxxxx
$1917
Mar 31, 2024
xxxxxxxxxxxxx
$118042
Mar 31, 2024
xxxxxxxxxxxxx
$1085772
Mar 31, 2024
xxxxxxxxxxxxx
$2265966

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
11,035,567Institution8.31%98,657,969
10,703,791Institution8.06%95,691,892
5,137,459Institution3.87%45,928,883
2,333,374Institution1.76%20,860,364
2,308,191Institution1.74%20,635,228
2,135,087Institution1.61%19,087,678
1,949,139Institution1.47%17,425,303
1,943,097Institution1.46%17,371,287
1,773,894Institution1.34%15,858,612
1,287,830Institution0.97%11,513,200

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
10,703,791Institution8.06%95,691,892
2,333,374Institution1.76%20,860,364
2,308,191Institution1.74%20,635,228
1,949,139Institution1.47%17,425,303
1,773,894Institution1.34%15,858,612
1,287,830Institution0.97%11,513,200
1,038,414Institution0.78%9,283,421
984,136Institution0.74%8,798,176
865,767Institution0.65%7,739,957
859,551Institution0.65%7,684,386

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,869,332Institution2.91%25,228,045
2,694,678Institution2.03%24,090,421
3,169,848Institution2.39%20,667,409
2,013,378Institution1.52%18,241,205
1,785,607Institution1.35%11,642,158
1,455,323Institution1.10%9,488,706
924,187Institution0.70%8,262,232
852,479Institution0.64%7,621,162
465,062Institution0.35%4,213,462
370,473Institution0.28%2,415,484

FAQ

Who Owns Relay Therapeutics (RLAY)?
According to the latest TipRanks data, approximately 15.54% of the company's stock is held by institutional investors, 33.94% is held by insiders, and 23.84% is held by retail investors.
    What percentage of Relay Therapeutics (RLAY) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 15.54% of Relay Therapeutics (RLAY) stock is held by institutional investors.
      What percentage of Relay Therapeutics (RLAY) stock is held by retail investors?
      According to the latest TipRanks data, approximately 23.84% of Relay Therapeutics (RLAY) stock is held by retail investors.
        Who owns the most shares of Relay Therapeutics (RLAY)?
        Vanguard owns the most shares of Relay Therapeutics (RLAY).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis